{"cluster": 20, "subcluster": 43, "abstract_summ": "Moreover, asymptomatic individuals evoked weaker S1 specific IgM and neutralizing antibody responses than mild patients.We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and spike (S) protein after symptom onset in the intensive care unit (ICU) and non-ICU patients.63 healthy contacts, 63 asymptomatic individuals, and 51 mild patients were enrolled in this study and screened using nucleic acid testing (NAT) and commercial kits of serum IgM and IgG antibodies against recombinant nucleoprotein (N) and spike (S) proteins of SARS-CoV-2.The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset.Asymptomatic and mild patients were classified into at least four types based on NAT and serological tests, especially 81% and 25.4% negative NAT but positive IgM/IgG responses, respectively.", "title_summ": "Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patientsAntibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practiceAntibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients", "title_abstract_phrases": "Moreover, asymptomatic individuals evoked weaker S1 specific IgM and neutralizing antibody responses than mild patients.Asymptomatic and mild patients were classified into at least four types based on NAT and serological tests, especially 81% and 25.4% negative NAT but positive IgM/IgG responses, respectively.63 healthy contacts, 63 asymptomatic individuals, and 51 mild patients were enrolled in this study and screened using nucleic acid testing (NAT) and commercial kits of serum IgM and IgG antibodies against recombinant nucleoprotein (N) and spike (S) proteins of SARS-CoV-2.We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and spike (S) protein after symptom onset in the intensive care unit (ICU) and non-ICU patients.The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset."}